"The voice of oncology in Massachusetts."


Complete List of FDA Oncology Approval Notifications

To see a complete list of FDA Oncology (Cancer) / Hematologic Malignancies Approval Notifications, visit the FDA's website.


Upcoming events


  • May 09, 2022 8:03 AM | Katy Monaco (Administrator)
    FDA Approves Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen. More Information
  • April 07, 2022 11:35 AM | Katy Monaco (Administrator)

    U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million.2,3 In accordance with the Accelerated Approval Program, continued approval may be contingent upon verification and description of clinical benefit from confirmatory evidence. More Information

  • April 04, 2022 7:25 AM | Katy Monaco (Administrator)

    Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. More Information. Please see full Prescribing Information.

  • March 28, 2022 7:32 AM | Katy Monaco (Administrator)

    Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. More Information

  • March 21, 2022 8:28 AM | Katy Monaco (Administrator)
    OpdualagTM (nivolumab and relatlimab-rmbw), a new,  first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. More Information

  • March 14, 2022 8:46 AM | Katy Monaco (Administrator)
    AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Please see the attached document for more information regarding the use of LYNPARZA in this new indication. Press Release
  • March 07, 2022 8:26 AM | Katy Monaco (Administrator)

    U.S. Food and Drug Administration (FDA) approved Opdivo®(nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles for adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC) in the neoadjuvant setting. More Information

  • March 01, 2022 8:23 AM | Katy Monaco (Administrator)

    U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. More Information

  • February 24, 2022 10:11 AM | Katy Monaco (Administrator)

    Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PYRUKYND® (mitapivat) in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, debilitating, lifelong hemolytic anemia. PYRUKYND® is a first-in-class, oral PK activator and the first approved disease-modifying therapy for this disease.  More Information Click here for prescribing information.

  • December 23, 2021 12:00 PM | Katy Monaco (Administrator)

    REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.  Prescribing Information.  Visit Kadmon at https://kadmon.com/.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software